Exagen Diagnostics, EndoChoice announce agreement for promoting diagnostic services to U.S. gastroenterologists

Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

Under the agreement, EndoChoice's experienced, gastroenterology-focused sales force will introduce Exagen's proprietary gene expression tests for the diagnosis of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).  Exagen developed these molecular tests through its discovery engine, Coperna®, which identified "gene activity signatures" associated with IBD and IBS.

Scott Glenn, Exagen's CEO said, "We are excited about the opportunity of partnering with EndoChoice to accelerate the adoption of our technology by gastroenterologists.  Our eXaIBD™ and eXaIBS™ tests have both high sensitivity and accuracy, helping to identify IBD and IBS from other diseases, avoiding an extensive series of exclusionary testing."

"EndoChoice is focused on satisfying the unmet needs of GI professionals by delivering innovative, best-in-class products and services," said Mark Gilreath, EndoChoice's CEO.  "We are pleased to offer Exagen's proprietary eXaIBD™ and eXaIBS™ tests because they provide a superior diagnostic tool to assist gastroenterologists and improve patient care."